BridgeMD
Stop Treatment in gout
EU CTIS ID: 2024-515714-40-00
What this study is testing
to demonstrate that oral ULT withdrawal in patients with gout in remission, monitored with US scans, is not inferior to maintaining oral ULT for the risk of flares at 2 years
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- • Age ≥ 18 years
- • Gout, defined according to the 2015 ACR/EULAR classification criteria
- • No flares for at least 2 years
- • No tophi
- • Currently receiving allopurinol or febuxostat taken for at least 2 years and SUA levels ≤ 60 mg/l
- • No urate deposit on ultrasound (score 0/24) at inclusion visit at both MTPs 1 and knees
You likely can't join if
- • Unstable systemic medical condition (e.g., New York Heart Association stage IV heart failure, recent myocardial infarction, advanced cancer)
- • History of allergy to allopurinol or febuxostat or one of the excipients • Association with
- • Association with azathioprine, mercaptopurine (cytostatics-antimetabolites)
- • Contraindications to experimental medicinal products or auxiliary medicinal products
- • CKD stage 4 (eGFR less than 30 ml/mn/1.73 m2)
- • Ongoing treatment with uricosurics (benzbromarone and probenecid) or uricase
See the full eligibility criteria
- • Age ≥ 18 years
- • Gout, defined according to the 2015 ACR/EULAR classification criteria
- • No flares for at least 2 years
- • No tophi
- • Currently receiving allopurinol or febuxostat taken for at least 2 years and SUA levels ≤ 60 mg/l
- • No urate deposit on ultrasound (score 0/24) at inclusion visit at both MTPs 1 and knees
- • Ability to provide informed consent
- • Health Insurance.
- • Unstable systemic medical condition (e.g., New York Heart Association stage IV heart failure, recent myocardial infarction, advanced cancer)
- • History of allergy to allopurinol or febuxostat or one of the excipients • Association with
- • Association with azathioprine, mercaptopurine (cytostatics-antimetabolites)
- • Contraindications to experimental medicinal products or auxiliary medicinal products
- • CKD stage 4 (eGFR less than 30 ml/mn/1.73 m2)
- • Ongoing treatment with uricosurics (benzbromarone and probenecid) or uricase
- • Patient on SMA (state medical aid-AME)
- • Participation in other clinical trial on medicinal product for human use
- • Women of childbearing age.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.